Abstract
At the end of the activity, participants will be able to: • Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2D). • Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2D. • Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2D and CKD. • Describe the benefits and limitations of the steroidal and nonsteroidal mineralocorticoid receptor antagonists in the treatment of patients with DKD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
